Covidien Hernia Mesh Litigation: MDL 3029 Status and Record

The Covidien hernia mesh litigation is a group of federal product liability cases about polyester surgical mesh implanted to repair hernias. The cases are consolidated as MDL 3029 in the District of Massachusetts before Judge Patti B. Saris, under the title In re Covidien Hernia Mesh Products Liability Litigation (No. II). The Judicial Panel on Multidistrict Litigation counted 2,479 actions pending as of October 1, 2026, out of 2,489 filed over the life of the proceeding. A first bellwether case went through expert and summary judgment rulings in 2026, and no reviewed order sets a trial date or reports a settlement.

What the device is

Symbotex Composite Mesh, the product at issue in the first bellwether case, is a nonabsorbable monofilament polyester mesh with an absorbable coating of porcine collagen and glycerol. The coating is intended to limit tissue attachment while the peritoneum heals (April 27, 2026 order). The FDA cleared it as a Class II device under section 510(k) on August 22, 2013, with Sofradim Production as the applicant (FDA 510(k) K131969). A 510(k) clearance is a substantial-equivalence determination; the April 27 order repeats the Supreme Court’s observation that such devices have “never been formally reviewed . . . for safety or efficacy.”

What is established vs. what is alleged

Established by the court record

• The consolidation exists. The JPML created MDL 3029 on June 6, 2022 and assigned it to Judge Saris in the District of Massachusetts, where Covidien LP is headquartered (transfer order).
• The case count is published. The panel’s October 1, 2026 report lists 2,479 actions pending and 2,489 total actions (JPML report).
• The first request to consolidate was denied. In August 2020 the panel denied a motion to centralize 12 actions as MDL 2953, finding that only a minimal number of federal actions were involved and that most of the more than 150 cases then pending were in state court (2020 order).
• The second request succeeded on a larger record. The 2022 motion covered 73 actions in seven districts, and the panel learned of ten more after filing. The parties represented that more than 4,700 cases were pending in a Massachusetts state court coordinated proceeding and 25 more in Minnesota state court (transfer order).
• Patterson is the first bellwether. The court has described Larry Patterson’s case, No. 22-cv-10153-PBS, as the first bellwether. He alleges that a Symbotex implant placed during a 2017 hernia repair adhered to his bowel and caused a bowel obstruction and hernia recurrence that required another operation in 2020 (June 2, 2026 order).
• The 2026 rulings address expert testimony. The court allowed in part and denied in part Covidien’s motions to exclude Dr. Stephen Ferzoco and Dr. Laura Plunkett, denied the motion to exclude Dr. Corey Deeken, and allowed in part and denied in part the motion to exclude Dr. David Michaels. The Michaels order barred opinions based on one explant sample for selection bias but permitted his general causation testimony (April 27 order; April 28 Deeken order; April 28 Plunkett order; June 5 order).
• Summary judgment was denied in part. On June 2, 2026 the court denied in part Covidien’s motion on specific causation and reserved the rest. Applying Alabama law, it predicted that the state supreme court would treat the “unavoidably unsafe product” question as a jury issue in most cases (June 2 order).

Alleged in the complaints

The transfer order summarized the plaintiffs’ theory: most plaintiffs allege that the polyester incites inflammation and a heightened foreign body response, is more brittle, and is more susceptible to fatigue fracture, breakage and fragmentation than alternative polymers. In many actions, plaintiffs also allege defects in the collagen barrier or the polylactic microgrips used in some Covidien mesh products (transfer order).

Those are allegations. The 2026 orders decided which expert testimony a jury may hear and which claims may proceed. None finds that Symbotex or any Covidien mesh caused a particular patient’s injury.

Where the claims stand procedurally

An MDL is not a trial and not a class action. It consolidates pretrial proceedings, mainly discovery and expert challenges, before one judge, while each plaintiff keeps an individual case. The difference is explained in MDL versus class action.

MDL 3029 remains on the panel’s pending list, and the October 2026 count shows that nearly every action ever filed is still pending. Patterson has passed the expert and partial summary judgment stage, and the June 2 order reserved the remaining grounds, including the safer-alternative-design argument. Other device dockets, such as the Paragard IUD litigation, follow the same structure. No reviewed order sets a trial date, reports a settlement, or describes mediation.

The FDA clearance and a separate recall

The FDA’s device enforcement database contains a 2018 voluntary removal of a different Covidien product, Parietex Composite Parastomal Mesh, models PCOPM15 and PCOPM20. Covidien initiated the removal on October 5, 2018, and the FDA classified it as Class II. The record states that the firm had received ten reports worldwide of mesh failure following parastomal hernia repair, with recurrence requiring additional surgery, and lists 7,333 units. The recall was terminated on May 7, 2020 (FDA report Z-0461-2019). That recall concerns a parastomal mesh, not Symbotex, and it is not a finding that Symbotex is defective.

Key dates

• August 22, 2013: The FDA clears Symbotex Composite Mesh under 510(k) K131969.
• October 5, 2018: Covidien initiates the voluntary removal of Parietex Composite Parastomal Mesh.
• August 7, 2020: The JPML denies centralization in MDL 2953.
• June 6, 2022: The JPML creates MDL 3029 and assigns Judge Saris.
• April 27 and 28, 2026: The court rules on the Ferzoco, Deeken and Plunkett expert motions.
• June 2, 2026: The court denies in part Covidien’s summary judgment motion and reserves the rest.
• October 1, 2026: The JPML reports 2,479 actions pending and 2,489 filed.

What this does not establish

Nothing in the reviewed record establishes that Symbotex or any other Covidien hernia mesh caused any patient’s injury. No trial has been held in the Patterson case, no verdict appears in the reviewed orders, and no settlement has been approved or announced in them. The 510(k) clearance is a substantial-equivalence determination. The 2018 recall concerns a different product. A pending case count measures filings, not the strength or value of any claim.

Frequently asked questions

Is this the same as the Davol and Bard litigation?

No. The Davol and Bard polypropylene mesh cases are consolidated separately as MDL 2846 in the Southern District of Ohio. The Covidien cases are MDL 3029 in Massachusetts and involve different defendants and a different product. The site’s hernia mesh litigation overview covers the Davol and Bard docket.

Has a court found that Symbotex causes bowel injury?

No. The 2026 rulings address whether experts may testify and whether claims survive summary judgment. Permitting causation testimony is an admissibility ruling, not a finding that the product caused any injury.

Is there a settlement?

No settlement appears in the reviewed court orders. The docket remains active, and the June 2026 orders continue to address pretrial motions. Any settlement would require a court filing, and readers should check the docket before relying on reports of one.

Sources

1. United States Judicial Panel on Multidistrict Litigation: “MDL Statistics Report - Distribution of Pending MDL Dockets by District” (link, accessed 2026-10-18)
2. United States Judicial Panel on Multidistrict Litigation: “Transfer Order, In re Covidien Hernia Mesh Products Liability Litigation (No. II), MDL No. 3029” (link, accessed 2026-10-18)
3. United States Judicial Panel on Multidistrict Litigation: “Order Denying Transfer, In re Covidien Hernia Mesh Products Liability Litigation, MDL No. 2953” (link, accessed 2026-10-18)
4. United States District Court for the District of Massachusetts: “Memorandum and Order on the Testimony of Dr. Stephen Ferzoco, In re Covidien Hernia Mesh Products Liability Litigation No. II, No. 22-md-03029-PBS (D. Mass. Apr. 27, 2026)” (link, accessed 2026-10-18)
5. United States District Court for the District of Massachusetts: “Memorandum and Order on the Testimony of Dr. Corey Deeken, In re Covidien Hernia Mesh Products Liability Litigation No. II, No. 22-md-03029-PBS (D. Mass. Apr. 28, 2026)” (link, accessed 2026-10-18)
6. United States District Court for the District of Massachusetts: “Memorandum and Order on the Testimony of Dr. Laura Plunkett, In re Covidien Hernia Mesh Products Liability Litigation No. II, No. 22-md-03029-PBS (D. Mass. Apr. 28, 2026)” (link, accessed 2026-10-18)
7. United States District Court for the District of Massachusetts: “Memorandum and Order on Summary Judgment, In re Covidien Hernia Mesh Products Liability Litigation No. II, No. 22-md-03029-PBS (D. Mass. June 2, 2026)” (link, accessed 2026-10-18)
8. United States District Court for the District of Massachusetts: “Memorandum and Order on the Testimony of Dr. David Michaels, In re Covidien Hernia Mesh Products Liability Litigation No. II, No. 22-md-03029-PBS (D. Mass. June 5, 2026)” (link, accessed 2026-10-18)
9. U.S. Food and Drug Administration: “510(k) Premarket Notification K131969, Symbotex Composite Mesh” (link, accessed 2026-10-18)
10. U.S. Food and Drug Administration: “Device Enforcement Report Z-0461-2019, Parietex Composite Parastomal Mesh” (link, accessed 2026-10-18)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.